companies / trogenix-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 102,600,000102.6M | ○ |
|---|---|---|
| founded | 2023 | |
| hq | Edinburgh, United Kingdom | |
| industry | unknown | |
| stage | series-a |
Trogenix is a biotech company developing precision cancer gene therapies using its Odysseus platform and Synthetic Super-Enhancers that target cancer-specific transcription factors. It serves patients with aggressive solid tumors such as brain cancer. Its differentiator is combining cell killing, immune activation, and protection in one therapy.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-10-01 | series-a | 86,400,00086.4M | null | ○ |
Nginx, WordPress 7.0, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, parallax.js, PHP, DoubleClick Floodlight, MySQL
| fact | status | src |
|---|---|---|
| Series A, $86.4M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |